Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus R-CHOP versus R-CHOP in previously untreated mantle cell lymphoma
CTR20212348Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of orelabrutinib in mantle cell lymphoma (MCL) (2 arms), sponsored by Innovent Biologics. Primary endpoint: Progression-free survival. Started Jan 2022; status: completed.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20212348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212348.